Clinical potential of <scp>DAS</scp>181 for treatment of parainfluenza‐3 infections in transplant recipients
B.B. Guzmán‐Suarez(Brigham and Women's Hospital), Sophia Koo(Dana-Farber Brigham Cancer Center), Rebecca Sanders(University of Cincinnati), Francisco M. Marty(Brigham and Women's Hospital), Richard B. Moss(Palo Alto University), David F. Wurtman(Pfizer (United States)), E. Vocca(Brigham and Women's Hospital), Lindsey R. Baden(Brigham and Women's Hospital), Fang Fang(Shenyang Medical College), Nicolas C. Issa(Dana-Farber Cancer Institute), Mary W. Buckley(Brigham and Women's Hospital), Erin T. Gilmore(Brigham and Women's Hospital)
Cited by 60
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981